TB-500 Mechanism of Action — Actin Sequestering, Angiogenesis & Anti-Inflammatory Signalling

*Proposed mechanisms of the thymosin β4 active-region fragment TB-500: G-actin sequestering, KLF2-mediated angiogenesis, AcSDKP release and anti-inflammatory cytokine modulation.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use.

Overview

TB-500 is a synthetic peptide corresponding to the active region of thymosin β4 (Tβ4), a 43-amino-acid actin-sequestering protein abundant in platelets, leukocytes and most cell types. The "TB-500 = active fragment" framing is the standard research distinction from the full-length molecule used in RegeneRx's clinical program.

Actin Sequestering

The conserved N-terminal "LKKTET" motif binds monomeric G-actin, regulating the G-actin / F-actin equilibrium critical for cell migration, wound contraction and immune cell trafficking. This actin-binding role is the canonical Tβ4 mechanism.

Angiogenesis — KLF2 / VEGF Pathway

Tβ4 upregulates KLF2 and downstream pro-angiogenic gene programs including VEGF, eNOS and thrombomodulin. Tube-formation, aortic-ring and chorioallantoic membrane assays all show accelerated angiogenesis with Tβ4 exposure.

AcSDKP Release

Tβ4 is hydrolysed by prolyl oligopeptidase to release N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), a tetrapeptide with documented antifibrotic, hematopoietic-protective and anti-inflammatory activity. AcSDKP is proposed as a downstream mediator of several Tβ4 effects.

Anti-Inflammatory Signalling

• Downregulation of NF-κB nuclear translocation
• Reduced pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
• Modulation of complement activation in cardiac ischemia models

Tissue Repair Models

Tβ4 accelerates corneal wound healing (basis of the RGN-259 program), cardiac repair after MI in murine models, and dermal wound healing across multiple species. The RegeneRx ophthalmic Phase 2 (RGN-259) provides the largest controlled human dataset for Tβ4 itself.

Frequently Asked Research Questions

Is the TB-500 fragment the same as full-length Tβ4?

No. TB-500 corresponds to the active region of Tβ4, not the full 43-amino-acid molecule. Both share the LKKTET actin-binding motif, but pharmacokinetics and safety datasets are not interchangeable.

What is AcSDKP and why does it matter?

AcSDKP is a tetrapeptide released by enzymatic cleavage of Tβ4. It is independently antifibrotic and hematopoietic-protective and is proposed as a downstream mediator of several Tβ4 effects beyond actin-sequestering.

How does Tβ4 promote angiogenesis?

Cell-based work shows Tβ4 upregulates KLF2 and downstream pro-angiogenic genes including VEGF and eNOS, accelerating endothelial tube formation independently of growth-factor supplementation.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Coskun T, et al. *LY3298176 (tirzepatide) — discovery of a dual GIP/GLP-1 agonist.* Mol Metab. 2018.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC-157.* Curr Pharm Des. 2018.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Falutz J, et al. *Tesamorelin in HIV-associated lipodystrophy.* N Engl J Med. 2007.

1. Pfaus JG, et al. *Bremelanotide — central melanocortin agonism.* Curr Sex Health Rep. 2007.

1. Khavinson VK, et al. *Epitalon — pineal-tetrapeptide telomerase activation.* Bull Exp Biol Med. 2003.

1. Imai S, Guarente L. *NAD+ and sirtuins in aging and disease.* Trends Cell Biol. 2014.